Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro," Bari, Italy.
Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro," Bari, Italy/Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
Mult Scler. 2021 Mar;27(3):430-438. doi: 10.1177/1352458520974366. Epub 2020 Nov 19.
No uniform criteria for a sensitive identification of the transition from relapsing-remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available.
To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA).
Relapsing-onset MS patients ( = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models.
SPMS identified by the DDA ( = 2343, 12.1%) were older, more disabled and with a faster progression to severe disability ( < 0.0001), than those identified by the ND ( = 3868, 20.0%). In both groups, the most consistent risk factors ( < 0.05) for SPMS were a multifocal onset, an age at onset >40 years, higher baseline EDSS score and a higher number of relapses; the most consistent protective factor was the disease-modifying therapy (DMT) exposure. DMT exposure during SP did not impact the risk of reaching irreversible EDSS 6.0.
A DDA definition of SPMS identifies more aggressive progressive patients. DMT exposure reduces the risk of SPMS conversion, but it does not prevent the disability accumulation after the SP transition.
目前尚无统一的标准来敏感识别从复发缓解型多发性硬化症(RRMS)向继发进展型多发性硬化症(SPMS)的转变。
使用两种定义(一种基于神经病学家判断(ND),另一种基于客观数据驱动算法(DDA))比较 SPMS 的危险因素。
从意大利多发性硬化症登记处提取了发病初即为复发型 MS 患者( = 19,318)。使用多变量 Cox 回归模型估计 SPMS 和 SP 转变后达到不可逆扩展残疾状态量表(EDSS)6.0 的风险因素。
DDA 识别的 SPMS( = 2343,12.1%)比 ND 识别的 SPMS( = 3868,20.0%)年龄更大、残疾程度更高且向严重残疾进展更快( < 0.0001)。在这两组中,最一致的 SPMS 危险因素( < 0.05)是多灶性发病、发病年龄>40 岁、基线 EDSS 评分较高和复发次数较多;最一致的保护因素是疾病修正治疗(DMT)的使用。SP 期间 DMT 的使用并未影响达到不可逆 EDSS 6.0 的风险。
DDA 定义的 SPMS 识别出更具侵袭性的进展性患者。DMT 的使用降低了 SPMS 转换的风险,但不能防止 SP 转变后的残疾累积。